BioDlink International Company Limited Announces Re-Designation of Non-Executive Director to Executive Director

Strategic Insights -

BioDlink International Company Limited's board of directors has announced that Mr. Fu, Shan, has been re-designated from a non-executive director to an executive director of the Company, effective from 11 October 2025. Mr. Fu will be responsible for leading and overseeing the management and development of the Group. He will also continue to serve as chairperson of the Board, chairperson of the Nomination Committee, and chairperson of the Strategy and ESG Committee. The re-designation is a significant move, as Mr. Fu will now be entitled to an annual director's fee, which will be determined by the Board based on his contributions, experience, and relevant duties. However, Mr. Fu has voluntarily agreed to receive a nominal annual director's fee of HK$1 for his service as an executive director during his term of office.

Key Takeaways:

  • Mr. Fu, Shan, has been re-designated from a non-executive director to an executive director of BioDlink International Company Limited, effective from 11 October 2025.
  • As an executive director, Mr. Fu will be responsible for leading and overseeing the management and development of the Group.
  • Mr. Fu will continue to serve as chairperson of the Board, chairperson of the Nomination Committee, and chairperson of the Strategy and ESG Committee.
  • The annual director's fee for Mr. Fu will be determined by the Board based on his contributions, experience, and relevant duties.
  • Mr. Fu has voluntarily agreed to receive a nominal annual director's fee of HK$1 for his service as an executive director during his term of office.
  • Mr. Fu has a diverse background, having worked in various roles, including as a managing partner and co-CEO of Vivo Capital LLC, a senior managing director at Blackstone (Shanghai) Equity Investment Management Company Limited, and a non-executive director of several other companies.
  • Mr. Fu has also served as a director of various companies, including LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., Sinovac Biotech Ltd., VISEN Pharmaceuticals, Genetron Holdings Limited, and InnoCare Pharma Limited.

Statistics:

  • Mr. Fu's annual director's fee will be determined based on his contributions, experience, and relevant duties within the Company.
  • The nominal annual director's fee for Mr. Fu's service as an executive director will be HK$1.
  • Mr. Fu has worked in various roles for over 20 years, with a focus on the biotechnology and healthcare sectors.
  • He has held directorship in subsidiaries of BioDlink International Company Limited and other companies.

Sources:

  • BioDlink International Company Limited's announcement (available at: https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1013/2025101300416.pdf)
  • Vivo Capital LLC's website (available at: https://www.vivocapital.com/)
  • Blackstone (Shanghai) Equity Investment Management Company Limited's website (available at: https://www.blackstone.com/)
  • LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.'s website (available at: https://www.lepu.com.cn/)
  • Sinovac Biotech Ltd.'s website (available at: https://www.sinovac.com/)
  • VISEN Pharmaceuticals' website (available at: https://www.visenpharma.com.cn/)
  • Genetron Holdings Limited's website (available at: https://www.genetronholdings.com/)
  • InnoCare Pharma Limited's website (available at: https://www.innocarepharma.com.cn/)